Table of contents

01 - Pre meeting briefing prepared by NICE  

02 - Full preceding guidance – Immunosuppressant therapy for renal transplantation in children and adolescents [TA99]  

03 – Assessment Report prepared by Peninsula Technology Assessment Group (PenTAG)  

04 – Assessment Report erratum by PenTAG  

05 – Assessment Report addendum: rapid review of non-RCT evidence by PenTAG  

06 – Assessment Report addendum: evaluation of the effect of a discount to the list price of prolonged release tacrolimus by PenTAG  

07 - Comments on the Assessment Report – Astellas  

08 - Comments on the Assessment Report – Novartis  

09 - Comments on the Assessment Report – Sanofi  

10 - Comments on the Assessment Report – The British Association for Paediatric Nephrology  

11 - Executive summary of technology submission – Astellas 

12 - Information about discounted prices - Astellas

13 - Consultee submission – The British Transplantation Society (BTS)  

14 - Consultee submission – The Efficacy and Safety of Prescribing in Transplantation (ESPRIT)  

15 - Clinical expert comments on the Assessment Report - Harden.  

16 - Clinical expert comments on the Assessment Report - Milford